ZURAMPIC Drug Patent Profile

Which patents cover Zurampic, and what generic alternatives are available?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

DrugPatentWatch^® Generic Entry Outlook for Zurampic

Zurampic was eligible for patent challenges on December 22, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2028. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZURAMPIC

International Patents:	144
US Patents:	8
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	92
Patent Applications:	329
Drug Prices:	Drug price information for ZURAMPIC
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZURAMPIC
DailyMed Link:	ZURAMPIC at DailyMed

See drug prices for ZURAMPIC

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZURAMPIC

NDA:

207988

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZURAMPIC

ZURAMPIC is protected by eleven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No

Expired US Patents for ZURAMPIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015

EU/EMA Drug Approvals for ZURAMPIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Grünenthal GmbH	Zurampic	lesinurad	EMEA/H/C/003932Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.,	Withdrawn	no	no	no	2016-02-18

International Patents for ZURAMPIC

When does loss-of-exclusivity occur for ZURAMPIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZURAMPIC around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2658846
Taiwan	201302718	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
China	102186827
South Korea	20110050709

Supplementary Protection Certificates for ZURAMPIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2135608	C20160027 00203	Estonia		PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
2135608	CR 2016 00034	Denmark		PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
2135608	PA2016024,C2135608	Lithuania		PRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2217577	1990005-9	Sweden		PRODUCT NAME: COMBINATION OF LESINURAD OR A PHARMACEUTICA LLY ACCEPTABLE SALT THEREOF AND ALLOPURINOL; REG. NO/DATE: EU/18/1300 20180827

ZURAMPIC Market Analysis and Financial Projection

Last updated: April 25, 2026

Zurampic (lesinurad) Market Dynamics and Financial Trajectory

What is Zurampic and how has its sales evolved?

Zurampic is lesinurad, an oral urate-lowering therapy indicated in the U.S. for gout patients who are inadequately controlled on xanthine oxidase inhibitors (XOI) and used in combination with a XOI. After launch, its U.S. performance transitioned into a steady decline as payer coverage tightened, clinical positioning remained narrow (adjunct only), and competitive alternatives expanded.

Indicative financial trajectory (U.S. commercial performance signals)

• Peak-to-decline profile: Like most “niche” urate-lowering agents, Zurampic did not sustain broad monotherapy adoption and remained largely adjunct to XOI.
• Premium pricing pressure: Payers increasingly focused on comparative value versus XOI optimization and newer urate-lowering pathways.
• Portfolio impact: The product became a smaller contributor to company revenue over time as marketing intensity and access remained constrained.

Revenue proxy from U.S. public filings

• U.S. sales and company commentary show contraction: In its annual reporting, AstraZeneca (the U.S. holder after acquisition of the relevant asset platform) described the revenue base as declining for older, smaller brands. This pattern aligns with Zurampic’s post-peak trajectory in the U.S. market. (AstraZeneca FY annual report; see citations below.) [1]

What market forces are driving Zurampic demand in gout treatment?

Zurampic’s commercial outcome is tightly linked to the gout care pathway and payer behavior around urate lowering.

1) Indication constraints: adjunct-only positioning

• Zurampic’s core label positions it for patients inadequately controlled on XOI, which limits addressable demand versus broad urate-lowering agents.
• Clinical practice trends favor XOI titration and adherence before adding a second urate-lowering mechanism, tightening the “add-on” funnel.

2) Payer coverage and formulary tightening

• ULT (urate-lowering therapy) formularies are sensitive to annual cost and comparative evidence.
• As multiple gout treatment options matured, payers shifted to preferred brands and generally required stronger justification for combination additions.

3) Competitive landscape

• XOI competitors: allopurinol and febuxostat remain backbone therapies for chronic gout management.
• Adjunct/other mechanisms: competing agents and evolving guidelines increased the difficulty of maintaining premium adjunct share once initial uptake wore off.

4) Treatment adherence and persistence

• Adjunct therapies depend on stable XOI background use and persistence.
• Any erosion in XOI adherence or patient selection reduces add-on conversion.

How have regulatory and commercial events affected the trajectory?

Regulatory actions and label dynamics change payer and prescriber behavior, with downstream effects on prescribing.

U.S. label history and access

• The U.S. label for Zurampic includes safety considerations associated with urate lowering and kidney-related risks, which can affect prescriber comfort and payer approval processes.
• These factors influence patient selection and persistence, both critical to maintaining sales in a narrow-use segment. (Drug label and FDA materials.) [2]

Broader ULT policy environment

• Over time, U.S. and global payer policies increasingly emphasized evidence-based selection and cost management in chronic disease medicines.
• For niche adjuncts, this often translates into weaker net pricing and lower patient coverage.

What is the likely commercial path to loss of exclusivity?

Loss of exclusivity drives a step-change in the competitive environment when generic or authorized competitors enter.

Patent and exclusivity posture (strategic relevance)

• Zurampic is exposed to generics once patent protection expires, with commercial impact strongest after exclusivity ends and real-world payer substitution accelerates.
• Patent-landscape risk is tied to:
  • primary compound and formulation protection,
  • method-of-use coverage if any,
  • and any exclusivity wrappers tied to regulatory approvals.

Patent challenge framework

• For products like lesinurad, the competitive risk after exclusivity is typically dominated by:
  • abbreviated new drug application pathways,
  • litigation outcomes,
  • and settlement terms that define generic launch timing.

Practical implication for financial trajectory

• Even before exclusivity loss, revenue often compresses due to pre-launch payer tightening and reduced channel stocking.
• Once competition arrives, revenue often falls faster than expected because gout ULT is typically chronic and substitution is straightforward when label allows.

How does Zurampic compare with other gout ULT products on market dynamics?

Zurampic behaves like a “narrow-lens” add-on in a market that structurally favors backbone urate-lowering agents.

Positioning comparison (commercial mechanics)

• XOI backbone therapies: larger eligible population, broader prescribing pattern, stronger persistence.
• Adjunct uricosurics: smaller addressable pool (add-on after XOI failure) and higher payer selectivity.
• Net effect: adjunct brands tend to show a steeper post-launch decline unless they gain guideline-anchored add-on status and durable formulary access.

Zurampic-specific takeaway

• Its commercial trajectory reflects limited indication breadth plus payer and prescriber gating, which magnifies decline once early adoption fades. The result is lower long-run revenue retention than backbone therapies.

Financial trajectory: what to expect under the next competitive phase

The next phase is driven by the intersection of:

• exclusivity and patent expiry,
• generic entry timing,
• payer substitution speed,
• and residual patient population that stays on therapy.

Key financial drivers

1. Unit volume erosion: substitution shifts patients to lower-cost options.
2. Net price compression: rebates and contracting dynamics intensify during generic entry.
3. Channel and inventory normalization: wholesalers adjust to new supply and pricing.
4. Product portfolio reallocation: sponsors reduce promotional spend as ROI falls.

Revenue shape

• Near-term: continued decline if competitive share erodes faster than line extensions or new evidence expands usage.
• At generic launch: revenue falls sharply with a lag of several quarters as coverage, switching, and prior authorizations normalize.

Business implications for R&D and investment

R&D lessons from Zurampic’s market mechanics

• Adjunct-only indications face a narrower “conversion runway” than backbone agents.
• Label-linked safety considerations can amplify payer selectivity and reduce persistence.
• Durable net sales require either broader indication expansion or guideline entrenchment that creates payer coverage stability.

Investment framework

• For niche add-on assets, value depends on maintaining net pricing and formulary access well beyond initial launch.
• Exclusivity and patent life are central to the downside case, because competitive substitution is structurally fast once legal barriers fall.

---

Key Takeaways

• Zurampic’s market dynamics are constrained by adjunct-only positioning for gout inadequately controlled on XOI, which narrows eligible demand.
• Commercial performance transitions into a post-peak decline driven by payer tightening, backbone-therapy optimization, and competitive alternatives.
• Financial trajectory is closely coupled to exclusivity and patent expiry, with generic entry typically producing a rapid revenue step-down via substitution and net price compression.
• The product illustrates how narrow-lens ULT brands face structurally higher risk to persistence and formulary stability than backbone urate-lowering therapies.

---

FAQs

1. What is Zurampic’s role in gout treatment?
   It is an oral urate-lowering therapy used in combination with a xanthine oxidase inhibitor for patients with gout inadequately controlled on XOI. [2]

2. Why does an adjunct gout drug often decline after launch?
   The add-on funnel is narrower, and payers often prioritize XOI optimization and lower-cost preferred alternatives, limiting volume growth once early adoption ends.

3. What tends to happen financially at generic entry for drugs like Zurampic?
   Revenue typically falls quickly due to patient switching, payer substitution, and net price compression after coverage changes.

4. What are the main market forces affecting Zurampic demand?
   Indication narrowness, payer formulary access, XOI optimization trends, and safety-linked prescribing and authorization behavior.

5. What is the strategic importance of patents for Zurampic’s outlook?
   Patent and exclusivity status governs the timing of generic substitution, which largely determines the speed and magnitude of revenue erosion after legal barriers end.

---

References

[1] AstraZeneca. (2024). AstraZeneca annual report and form 20-F (financial reporting for FY 2023). AstraZeneca.
[2] U.S. Food and Drug Administration. (n.d.). Zurampic (lesinurad) prescribing information / label. FDA.